LIDDS AB develops pharmaceutical products for cancer and other diseases with NanoZolid technology. Its pipeline include NZ-Liproca Depot, NZ-DTX, NZ-DOX, NZ-IO, NZ-TLR9 and NZ-STING. The company was founded on November 4, 1999 and is headquartered in Uppsala, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company